Comparative Proteomic Approach Identifies PKM2 and Cofilin-1 As Potential Diagnostic, Prognostic and Therapeutic Targets for Pulmonary Adenocarcinoma

Overview

Journal PLoS One

Specialties General Medicine
Science

Date 2011 Nov 17

PMID 22087286

Citations 33

Authors

Xing-Chen Peng

Feng-Ming Gong

Yu-Wei Zhao

Liang-Xue Zhou

Ying-Wei Xie

Hong-Li Liao

Hong-Jun Lin

Zhi-Yong Li

Ming-Hai Tang

Ai-Ping Tong

Affiliations

Soon will be listed here.

Abstract

Lung cancer is the leading cause of cancer-related death in the world. Non-small cell lung carcinomas (Non-SCLC) account for almost 80% of lung cancers, of which 40% were adenocarcinomas. For a better understanding of the molecular mechanisms behind the development and progression of lung cancer, particularly lung adenocarcinoma, we have used proteomics technology to search for candidate prognostic and therapeutic targets in pulmonary adenocarcinoma. The protein profile changes between human pulmonary adenocarcinoma tissue and paired surrounding normal tissue were analyzed using two-dimensional polyacrylamide gel electrophoresis (2-DE) based approach. Differentially expressed protein-spots were identified with ESI-Q-TOF MS/MS instruments. As a result, thirty two differentially expressed proteins (over 2-fold, p<0.05) were identified in pulmonary adenocarcinoma compared to normal tissues. Among them, two proteins (PKM2 and cofilin-1), significantly up-regulated in adenocarcinoma, were selected for detailed analysis. Immunohistochemical examination indicated that enhanced expression of PKM2 and cofilin-1 were correlated with the severity of epithelial dysplasia, as well as a relatively poor prognosis. Knockdown of PKM2 expression by RNA interference led to a significant suppression of cell growth and induction of apoptosis in pulmonary adenocarcinoma SPC-A1 cells in vitro, and tumor growth inhibition in vivo xenograft model (P<0.05). In addition, the shRNA expressing plasmid targeting cofilin-1 significantly inhibited tumor metastases and prolonged survival in LL/2 metastatic model. While additional works are needed to elucidate the biological significance and molecular mechanisms of these altered proteins identified in this study, PKM2 and cofilin-1 may serve as potential diagnostic and prognostic biomarkers, as well as therapeutic targets for pulmonary adenocarcinoma.

Citing Articles

Construction of a prognostic model for lung adenocarcinoma based on membrane-tension-related genes.

Zhu P, Teng Z, Yang W, Zhang D, Wang B, Yang Z J Thorac Dis. 2023; 15(4):2098-2115.

PMID: 37197492 PMC: 10183546. DOI: 10.21037/jtd-23-396.

The role of activated androgen receptor in cofilin phospho-regulation depends on the molecular subtype of TNBC cell line and actin assembly dynamics.

Tahtamouni L, Alzghoul A, Alderfer S, Sun J, Ahram M, Prasad A PLoS One. 2022; 17(12):e0279746.

PMID: 36584207 PMC: 9803305. DOI: 10.1371/journal.pone.0279746.

Cofilin-1 as a potential biomarker for infection.

Xie Y, Zhang Z, Zhang M, Cao H Exp Ther Med. 2022; 23(4):253.

PMID: 35261625 PMC: 8855514. DOI: 10.3892/etm.2022.11178.

The potential role of cofilin-1 in promoting triple negative breast cancer (TNBC) metastasis via the extracellular vesicles (EVs).

Howard J, Goh C, Gorzel K, Higgins M, McCann A Transl Oncol. 2021; 15(1):101247.

PMID: 34678587 PMC: 8529549. DOI: 10.1016/j.tranon.2021.101247.

Overexpressed Proteins in HCC Cell-Derived Exosomes, CCT8, and Cofilin-1 Are Potential Biomarkers for Patients with HCC.

Cho H, Baek G, Yoon M, Ahn H, Son J, Kim S Diagnostics (Basel). 2021; 11(7).

PMID: 34359304 PMC: 8307801. DOI: 10.3390/diagnostics11071221.

References

Tanaka T, Harano Y, Sue F, Morimura H . Crystallization, characterization and metabolic regulation of two types of pyruvate kinase isolated from rat tissues. J Biochem. 1967; 62(1):71-91. DOI: 10.1093/oxfordjournals.jbchem.a128639. View

Eigenbrodt E, Kallinowski F, Ott M, Mazurek S, Vaupel P . Pyruvate kinase and the interaction of amino acid and carbohydrate metabolism in solid tumors. Anticancer Res. 1998; 18(5A):3267-74. View

Qu S, Long J, Cai Q, Shu X, Cai H, Gao Y . Genetic polymorphisms of metastasis suppressor gene NME1 and breast cancer survival. Clin Cancer Res. 2008; 14(15):4787-93. PMC: 2713865. DOI: 10.1158/1078-0432.CCR-08-0083. View

Chen G, Gharib T, Wang H, Huang C, Kuick R, Thomas D . Protein profiles associated with survival in lung adenocarcinoma. Proc Natl Acad Sci U S A. 2003; 100(23):13537-42. PMC: 263849. DOI: 10.1073/pnas.2233850100. View

Steeg P, Bevilacqua G, Kopper L, Thorgeirsson U, Talmadge J, Liotta L . Evidence for a novel gene associated with low tumor metastatic potential. J Natl Cancer Inst. 1988; 80(3):200-4. DOI: 10.1093/jnci/80.3.200. View

Schneider J, Neu K, Grimm H, Velcovsky H, Weisse G, Eigenbrodt E . Tumor M2-pyruvate kinase in lung cancer patients: immunohistochemical detection and disease monitoring. Anticancer Res. 2002; 22(1A):311-8. View

Yokota N, Koizume S, Miyagi E, Hirahara F, Nakamura Y, Kikuchi K . Self-production of tissue factor-coagulation factor VII complex by ovarian cancer cells. Br J Cancer. 2009; 101(12):2023-9. PMC: 2795428. DOI: 10.1038/sj.bjc.6605406. View

Slebos R, Kibbelaar R, Dalesio O, Kooistra A, Stam J, Meijer C . K-ras oncogene activation as a prognostic marker in adenocarcinoma of the lung. N Engl J Med. 1990; 323(9):561-5. DOI: 10.1056/NEJM199008303230902. View

Gygi S, Rochon Y, Franza B, Aebersold R . Correlation between protein and mRNA abundance in yeast. Mol Cell Biol. 1999; 19(3):1720-30. PMC: 83965. DOI: 10.1128/MCB.19.3.1720. View

10.

Steeg P . Tumor metastasis: mechanistic insights and clinical challenges. Nat Med. 2006; 12(8):895-904. DOI: 10.1038/nm1469. View

11.

Palmieri D, Horak C, Lee J, Halverson D, Steeg P . Translational approaches using metastasis suppressor genes. J Bioenerg Biomembr. 2006; 38(3-4):151-61. DOI: 10.1007/s10863-006-9039-9. View

12.

Shi H, Li D, Zhang J, Wang Y, Yang L, Zhang H . Silencing of pkm2 increases the efficacy of docetaxel in human lung cancer xenografts in mice. Cancer Sci. 2010; 101(6):1447-53. PMC: 11158281. DOI: 10.1111/j.1349-7006.2010.01562.x. View

13.

Lee E, Kim S, Kwark Y, Kim J . Heterogeneous nuclear ribonuclear protein C is increased in the celecoxib-induced growth inhibition of human oral squamous cell carcinoma. Exp Mol Med. 2006; 38(3):203-9. DOI: 10.1038/emm.2006.25. View

14.

Zhang B, Chen J, Chen D, Wang G, Shen P . Tumor type M2 pyruvate kinase expression in gastric cancer, colorectal cancer and controls. World J Gastroenterol. 2004; 10(11):1643-6. PMC: 4572770. DOI: 10.3748/wjg.v10.i11.1643. View

15.

Grubb 3rd R, Franks M, Toro J, Middelton L, Choyke L, Fowler S . Hereditary leiomyomatosis and renal cell cancer: a syndrome associated with an aggressive form of inherited renal cancer. J Urol. 2007; 177(6):2074-9. DOI: 10.1016/j.juro.2007.01.155. View

16.

Ouatas T, Salerno M, Palmieri D, Steeg P . Basic and translational advances in cancer metastasis: Nm23. J Bioenerg Biomembr. 2003; 35(1):73-9. DOI: 10.1023/a:1023497924277. View

17.

Launonen V, Vierimaa O, Kiuru M, Isola J, Roth S, Pukkala E . Inherited susceptibility to uterine leiomyomas and renal cell cancer. Proc Natl Acad Sci U S A. 2001; 98(6):3387-92. PMC: 30663. DOI: 10.1073/pnas.051633798. View

18.

Christofk H, Vander Heiden M, Harris M, Ramanathan A, Gerszten R, Wei R . The M2 splice isoform of pyruvate kinase is important for cancer metabolism and tumour growth. Nature. 2008; 452(7184):230-3. DOI: 10.1038/nature06734. View

19.

Horio Y, Takahashi T, Kuroishi T, Hibi K, Suyama M, Niimi T . Prognostic significance of p53 mutations and 3p deletions in primary resected non-small cell lung cancer. Cancer Res. 1993; 53(1):1-4. View

20.

Petricoin E, Zoon K, Kohn E, Barrett J, Liotta L . Clinical proteomics: translating benchside promise into bedside reality. Nat Rev Drug Discov. 2002; 1(9):683-95. DOI: 10.1038/nrd891. View